Bioinformatics validation of clinical and pathway and process enrichment analysis in BCa patients confirmed that gain/amplification of TRAF6 is associated with secondary BCa in bone (P = 0.0079), and poor survival rate (P < 0.05). In BCa patients, high expression of TRAF6 (Hazard Ratio: 1.01, CI: 1.01, 1.01, P < 0.00001) is associated with poor survival rate. ![]() We identified 14 in vitro, 11 in vivo and 4 human articles. To explore which TRAF represents a potential druggable target for BCa treatment, we searched Medline, Web of Science and Scopus for relevant studies from inception to June 27, 2021. ![]() However, the TRAF family constitutes of seven members that exhibit distinct and overlapping functions. ![]() ![]() TRAF6 has emerged as a key regulator of breast cancer (BCa).
0 Comments
Leave a Reply. |